Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplanta...
Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate o...
Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.
Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral rating and annou...
Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planni...
UBS analyst Colin Bristow maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $56 to ...
JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and lowers the price target f...
